-
NeuroSense | Reporting Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NASDAQ: NRSN Introduction NeuroSense, a groundbreaking biopharmaceutical company, is set to release the highly anticipated topline results of its Phase 2b clinical trial for ALS (Amyotrophic Lateral Sclerosis) on December 5, 2023. This milestone event marks a significant step forward in the search for new treatment options for this devastating disease. In this article, we…
-
BrainStorm Cell Therapeutics | Announces FDA Advisory Committee Meeting to Review NurOwn® PDUFA Target Action Date Scheduled for December 8, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that the US FDA has granted the company a meeting to discuss the regulatory path forward for NurOwn® in ALS. The meeting, scheduled for December 6, 2023, will focus on plans for a Special Protocol Assessment (SPA) for a confirmatory Phase 3 trial in ALS. BrainStorm aims to…